The Role of Emerging Biologic Therapies in Reducing Inflammation and Improving Patient Outcomes with Relapse-Remitting Multiple Sclerosis

http://academiccme.com/wp-content/uploads/2016/12/iStock-538240189-wpcf_400x400.jpg

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 1.0 AMA PRA Category 1 Credit(s)™
Activity Dates: December 29, 2016 - December 30, 2017

 

Program Overview

This CME program will focus on the new and emerging biological therapeutic options in the management of patients with relapse-remitting Multiple Sclerosis (RRMS). This activity educates healthcare providers involved in the management of patients with RRMS to evaluate patient outcomes and the responsiveness to new therapeutic agents. The expert faculty will discuss the science behind new and emerging biological therapies and studies. Upon completion of this activity physicians will gain insight into improvement of outcomes in patients with RRMS.

Target Audience

Neurologists, and other healthcare professionals who care for patients with MS.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the role of inflammation and immunomodulatory targets in relapse-remitting multiple sclerosis.
  2. Examine clinical trial data of current and emerging biologic therapies for the treatment of relapse-remitting multiple sclerosis.
  3. Incorporate recent science into individualized treatment strategies to improve cognitive function and overall quality of life for patients with relapsing-remitting multiple sclerosis.

 

Faculty

markowitzClyde Markowtiz, MD
Director, MS Center
Associate Professor, Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Clyde Markowitz, MD Consultant/Advisor: Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Opexa Therapeutics, Inc.; F. Hoffmann-La Roche Ltd and Teva Pharmaceutical Industries Ltd

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON




Biogen